AI assistant
Fagron N.V. — Capital/Financing Update 2016
May 2, 2016
3949_iss_2016-04-30_dac82e63-959b-4e2d-a25a-fbc39a0f2e55.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Regulated information Waregem (Belgium)/Rotterdam (The Netherlands)1 , 30 April 2016
Fagron announces today that there are no changes in the Guarantor List in accordance with the Guarantee Declaration dated 12 June 2012 regarding the € 225,000,000 4.75% Bond with maturity date 2 July 2017.
The list of Guarantors, in accordance with Article 10.4 of the Guarantee Declaration, is available at investors.fagron.com.
In accordance with Condition 10 (b) of the Bonds a new Compliance Certificate is published. This Compliance Certificate is available at investors.fagron.com.
In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.
For more information:
Constantijn van Rietschoten Chief Marketing Officer Tel. +31 6 53 69 15 85 [email protected]
Fagron profile
Fagron is a scientific pharmaceutical R&D business focused on optimising and innovating personalised pharmaceutical care. Fagron provides Fagron Specialty Pharma Services, Fagron Trademarks and Fagron Essentials to pharmacies, clinics and hospitals in 32 countries worldwide.
The Belgian company Fagron NV is located in Waregem and is listed on Euronext Brussels and Euronext Amsterdam. The operational activities of Fagron are driven by the Dutch company Fagron BV. The head office of Fagron BV is located in Rotterdam.